Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer

Published:2021-01-01 Issue:1 Volume:24 Page:1185-1193
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Paladini Luciano¹²^ORCID,da Veiga Cássia Rita Pereira³⁴^ORCID,Cerqueira Érica³^ORCID,Chabrol Haas Laura³,Datz Abadi Márcia³,Baldotto Clarissa Seródio⁵⁶^ORCID

Affiliation:

1. Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, Brazil

2. Oncocentro (Grupo Oncoclinicas do Brasil), Uberlândia, Brazil

3. MSD Brazil, São Paulo, Brazil

4. Universidade Federal do Paraná, Curitiba, Brazil

5. Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

6. Oncologia D’Or, Rio de Janeiro, Brazil

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1993864

Reference42 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Lung cancer in Brazil

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

4. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indirect Costs Due to Lung Cancer-Related Premature Mortality in Four European Countries;Advances in Therapy;2023-05-17